Skip to content

The ClariVein device using liquid Polidocanol and foam for the treatment of great saphenous vein incompetence : A dose finding study.

The ClariVein device using liquid Polidocanol and foam for the treatment of great saphenous vein incompetence : A dose finding study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON26113
Enrollment
600
Registered
2011-07-29
Start date
2011-09-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incompetence of the great saphenous vein Varicose veins ClariVein Minimal invasive

Interventions

The procedure will be identical for every patient, except for the dosage and form of the chemical component. The patient will be examined by ultrasound to identify the GSV at the knee level. This will

Sponsors

academisch ziekenhuis maastricht (azM).
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who are first time treated for incompetence of the VSM, proven with duplex ultrasound examination; 2. CEAP classification C2-C4; 3. All patients with informed consent.

Exclusion criteria

Exclusion criteria: 1. Age 40; 8. Very tortuous pace of GSV which bends at an angle of >90 º or more twists follow each other; 9. Allergy or contraindication to Polidocanol; 10. GSV bigger than 12mm.

Design outcomes

Primary

MeasureTime frame
Our primary endpoint is the anatomical success rate of the treated GSV after 6 months, defined as occlusion confirmed by ultrasound of at least 85% which correlates to 24,5cm of the treated 30cm.

Secondary

MeasureTime frame
1. Mean VCSS change (evaluated at mentioned time points); 2. Pain score during procedure (VAS); 3. Two weeks post-preocedure pain score (VAS); 4. Health status (using the SF36 the general health status will be evaluated at mentioned time points); 5. Disease related quality of life (using the AVVQ, the quality of life related to the disease will be evaluated at mentioned time points); 6. Adverse events; 7. Patient satisfaction measured in separate scores.

Contacts

Public ContactY.L. Lam

Y.L. Lam MD, P. Debyelaan 25

yeelai_1@hotmail.com+31 (0)6 45152512

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)